Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 61 - 70 of 133

Selected Filters:
12 October 2023

CAB PrEP Value Chain Situation Analysis – Uganda – 2022

This analysis was developed in the fall of 2022 by members of the MOSAIC consortium. This analysis is based on several inputs, including a desk review, secondary research, and interviews with key stakeholders in Uganda.

Normative Guidance/Policies, Service Delivery

Document
9 October 2023

Efficacy, Safety, Tolerability, and Pharmacokinetics of Long-acting Injectable Cabotegravir for HIV Pre-exposure Prophylaxis in Transgender Women: A secondary analysis of the HPTN 083 trial

This article from the Lancet HIV discusses the results of a secondary analysis of data from the HPTN 083 trial of cabotegravir for PrEP, looking specifically at the cohort of transgender women included in the study.

Research

External Link
19 September 2023

Rapid Landscape Analysis of National Vertical Transmission Policies for Inclusion of PrEP for Pregnant and Breastfeeding People

Elimination of vertical transmission of HIV will require expanded access to HIV prevention strategies, such as PrEP, for pregnant and breastfeeding people. Guidance from the World Health Organization (WHO) supports provision of HIV pre-exposure prophylaxis (PrEP) to pregnant and breastfeeding people (PBFP) who are at continuing substantial risk of HIV infection. Evidence has shown that…

Normative Guidance/Policies, Service Delivery

Document
24 August 2023

Injectable PrEP Factsheet for MSM Advocates and Community Members in the Asia-Pacific Region

This factsheet raises awareness of injectable cabotegravir (CAB) for PrEP and describes actions community members can take to advocate for the approval and availability of CAB for PrEP in their country in the Asia Pacific region. This factsheet is designed for gay, bisexual, and other men who have sex with men advocates and community members-…

Normative Guidance/Policies

Document
24 August 2023

Value Chain Situation Analysis for CAB PrEP – Interview Guide

The interview question bank is designed to help identify questions to ask stakeholders in interviews to inform a situation analysis for CAB PrEP.

Normative Guidance/Policies

Document
24 August 2023

Value Chain Situation Analysis for CAB PrEP – Overview Guide

This tool can be used by policymakers or others supporting policy development for CAB PrEP (e.g., nongovernmental organizations, donors) to conduct an analysis to assess the existing situation for the introduction of the new product. The guide facilitates a structured process in three steps to support initial planning for CAB PrEP introduction: data collection, stakeholder…

Normative Guidance/Policies

Document
11 August 2023

Feasibility of Long Acting Injectable Cabotegravir PrEP Initiation and Administration by Community Health Workers and Early Aspects of the PrEP Injection Care Continuum in a Primary Care Center in Washington, D.C.

This poster presentation, delivered at IAS 2023 by the Whitman-Walker Institute, describes the integration of long acting injectable cabotegravir for PrEP, administered by community health workers, or non medically licensed staff, in a primary health clinic in Washington, D.C., USA.

Research, Service Delivery

Document
10 August 2023

Shaping and Coordinating the Implementation Science Agenda for Injectable Cabotegravir for PrEP: The role of the Biomedical Prevention Implementation Collaborative (BioPIC)

This article from JIAS describes the coordinated approach taken by the Biomedical Prevention Implementation Collaborative (BioPIC) to ensure questions regarding delivery of cabotegravir (CAB) for PrEP are addressed so that CAB can be introduced in low- and middle-income countries in timely, acceptable and effective ways.

Research

External Link
10 August 2023

Counterfactual Estimation of Efficacy against Placebo for Novel PrEP Agents Using External Trial Data: Example of injectable cabotegravir and oral PrEP in women

This article from JIAS uses estimated prevention efficacy against a counterfactual placebo to provide information on the use of cabotegravir for PrEP and oral PrEP compared to no intervention.

Research

External Link
16 June 2023

Country Planning for Product Introduction Matrix

AVAC’s Country Planning for Product Introduction Matrix tracks key indicators for the introduction of new PrEP products by country, including regulatory status, late stage clinical trials and implementation research, procurement plans, and recent oral PrEP provision.

Research, Service Delivery

External Link